Navigation Links
Hard To Treat Diseases (HTDS) Closes Acquisition of Mellow Hope, China
Date:2/20/2009

BEIJING, Feb. 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that it has closed the merger agreement with Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope). The acquisition has been structured through a Belize based corporation; HTDS Enterprises, Inc., which is the parent company of Mellow Hope. The acquisition is valued at $8.75 million USD on an all-stock basis. The company will issue 3.5 billion restricted shares valued at 0.0025 to Mellow Hope. This will bring the outstanding share structure to 4.75 billion shares.

The merger was announced in a formal televised ceremony on Monday, February 16th. A sampling of television and press coverage can be viewed at the following websites;

    -   Television: www.sztv.com.cn
    -   Shanghai Security Daily and China Security Daily Report:
       http://www.cnstock.com/paper_new/html/2009-02/17/content_66969010.htm
    -   Hong Kong and China Phoenix TV report:
       http://finance.ifeng.com/zq/qqgs/zbsc/20090218/383646.shtml
    -   China investment Daily report:http://www.chnvc.com/news/a11447.html
    -   China's largest internet portal: 'Sohu report':
       http://stock.sohu.com/20090217/n262295189.shtml
    -   China largest finance portal 'JRJ.com':
       http://finance.jrj.com.cn/2009/02/1806113600127.shtml

The agreement will see Mellow Hope join Slavica Bio Chem as an active operating division of HTDS. Located in Serbia, Slavica's primary focus involves the enhancement and modification of existing approved drugs to achieve chemical repair of damage to the CNS (central nervous system) by diseases like MS (Multiple Sclerosis), SARS, Hepatitis C and HIV.

Mellow Hope is the biggest exporter of Biological Vaccines in China, and has a product line that encompasses vaccines for hepatitis A Vaccine, Group A,C,Y,W135 meningococcal polysaccharide vaccine, influenza, tetanus, diphtheria and other diseases; cerebroprotein hydrolysate for injection and active pharmaceutical ingredient (or APIs).

Mellow Hope's Hepatitis A Vaccine (sold under the brand name MEVAC-A) will enter the Thailand market for the first time this March. Additionally, the vaccine was recently certified in Russia, and will be marketed there beginning this May. In total, the Company is in the process of registration and clinical trials in more than 20 countries in Southeast Asia, Latin America and East Europe.

Plans for growth also include building of a larger cold warehouse, developing new vaccines, such as HPV and the establishment of new offices in Yunnan, Wuhan, Kunming as well as India, and the Philippines.

Mellow Hope revenues are currently in excess of $15 million USD.

HTDS CEO, Shimin (Terry) Yuan, commented; "With the full resources of a publicly traded company, and medical experts and management in place on two continents, there will be many opportunities to create synergies between the companies. Despite issues related to the global economic slowdown, there are very many Companies in China such as Mellow Hope that will continue to expand and grow at a rapid pace."

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT: For scientific dialogue and inquiry only, contact Andrea Zecevic via e-mail at azconsulting2001@gmail.com; For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Advances May Treat Stroke Faster, Better
2. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
3. High Achieving Los Angeles Charter School to Hold Health Fair Offering Free Medical Screening, Treatment and Information to Students and Their Families
4. SOLX Announces 1000th Gold Shunt Implantation Milestone for Glaucoma Treatment
5. New therapy with stem cells to treat Crohns disease
6. Landmark Trial Provides Vital Information for Cardiac Disease Treatment
7. Research increases possibilities of personalizing treatment of infant osteosarcoma
8. Renaissance Laser & Vein Institute (LaserandVeinclinic.com) Provides Top Notch Varicose Vein Treatment
9. Public Cancer Center Becomes First in South-East Asia to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
10. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
11. Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, ... and organizations with the tools and information to lower the costs, and increase ... the cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
(Date:2/6/2016)... , ... February 06, 2016 ... ... 303-368-6225 , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE ... perioperative nurses in the world with an estimated 5000 perioperative nurses in ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is ... (YUCC) . This event brings together top non-profit leaders, ultimate organizations, and coaches from ... Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and Education, describes this ...
(Date:2/6/2016)... Viejo, CA (PRWEB) , ... February 06, 2016 , ... ... quickly and easily add warm color grades to their footage. A LUT is a ... every pixel's color to the corresponding color indicated by the table. By manipulating each ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Patients in Alabama ... focused ultrasound (HIFU) therapy no longer have to travel out ... its partnership with Urology Centers of Alabama to ... FDA-cleared procedure for qualifying patients. Alabama ... in the treatment of prostate cancer using many different modalities. ...
(Date:2/5/2016)... 5, 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ... CEO, will be presenting at Source Capital Group,s 2016 Disruptive ... at 2:15 p.m. ET on Wednesday, February 10, ... discussion taking place at 3:15 p.m. ET. http://www.aethlonmedical.com ... hour after the conclusion of the live event. The panel ...
(Date:2/5/2016)... 5, 2016 Dehaier Medical Systems Ltd. ... "Company"), which develops, markets and sells medical devices ... China and international markets, today announced ... to concentrate the Company,s resources to develop its ... and to focus more on its major businesses. ...
Breaking Medicine Technology: